Galvani, Elena
Mundra, Piyushkumar A.
Valpione, Sara
Garcia-Martinez, Pablo
Smith, Matthew
Greenall, Jonathan
Thakur, Rohit
Helmink, Beth
Andrews, Miles C. http://orcid.org/0000-0003-1231-8641
Boon, Louis
Chester, Christopher
Gremel, Gabriela
Hogan, Kate
Mandal, Amit
Zeng, Kang
Banyard, Antonia
Ashton, Garry
Cook, Martin
Lorigan, Paul http://orcid.org/0000-0002-8875-2164
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Dhomen, Nathalie
Marais, Richard http://orcid.org/0000-0001-7484-4183
Funding for this research was provided by:
Harry J. Lloyd Charitable Trust (Career Development Award)
Wellcome Trust (100282/Z/12/Z)
Cancer Research UK (A27412 and A22902)
Article History
Received: 21 November 2019
Accepted: 21 January 2020
First Online: 12 February 2020
Competing interests
: R.M. serves as a consultant for Pfizer, and has a drug discovery program with Basilea Pharmaceutica. As a former employee of the ICR, he may benefit financially from drug discovery programs that are commercialized. M.C.A. reports advisory board participation and honoraria from Merck Sharp and Dohme, outside the submitted work. P.L. serves as paid advisor/speaker for Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novartis, Amgen, Pierre Fabre, Nektar, Melagenix. P.L. reports travel support from Bristol-Myers Squibb and Merck Sharp and Dohme, and receives research support from Bristol-Myers Squibb. J.A.W. is an inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb. J.A.W. serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. J.A.W. also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb, and Novartis. The remaining authors declare no competing interests.